NCT00696020 - Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD) | Biotech Hunter

Enrollment

360

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

February 28, 2009

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

BI 1744 CL/tiotropium bromide fixed dose combination

BI 1744 CL plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation

DRUG

tiotropium bromide

tiotropium bromide; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation

DEVICE

Respimat® Inhaler

Trial Locations (37)

Unknown

1237.4.0118 Boehringer Ingelheim Investigational Site, Riverside

1237.4.0103 Boehringer Ingelheim Investigational Site, San Diego

1237.4.0115 Boehringer Ingelheim Investigational Site, Wheat Ridge

1237.4.0105 Boehringer Ingelheim Investigational Site, Clearwater

1237.4.0110 Boehringer Ingelheim Investigational Site, DeLand

1237.4.0117 Boehringer Ingelheim Investigational Site, Tampa

1237.4.0104 Boehringer Ingelheim Investigational Site, Coeur d'Alene

1237.4.0120 Boehringer Ingelheim Investigational Site, Edina

1237.4.0112 Boehringer Ingelheim Investigational Site, Minneapolis

1237.4.0119 Boehringer Ingelheim Investigational Site, Saint Charles

1237.4.0114 Boehringer Ingelheim Investigational Site, Raleigh

1237.4.0102 Boehringer Ingelheim Investigational Site, Philadelphia

1237.4.0111 Boehringer Ingelheim Investigational Site, Charleston

1237.4.0106 Boehringer Ingelheim Investigational Site, Spartanburg

1237.4.0107 Boehringer Ingelheim Investigational Site, Spartanburg

1237.4.0123 Boehringer Ingelheim Investigational Site, Knoxville

1237.4.0122 Boehringer Ingelheim Investigational Site, Killeen

1237.4.0109 Boehringer Ingelheim Investigational Site, New Braunfels

1237.4.0108 Boehringer Ingelheim Investigational Site, Richmond

1237.4.0116 Boehringer Ingelheim Investigational Site, Spokane

1237.4.0121 Boehringer Ingelheim Investigational Site, Tacoma

1237.4.0101 Boehringer Ingelheim Investigational Site, Morgantown

1237.4.0203 Boehringer Ingelheim Investigational Site, Winnipeg

1237.4.0201 Boehringer Ingelheim Investigational Site, Mississauga

1237.4.0202 Boehringer Ingelheim Investigational Site, Toronto

1237.4.0205 Boehringer Ingelheim Investigational Site, Toronto

1237.4.0208 Boehringer Ingelheim Investigational Site, Toronto

1237.4.0206 Boehringer Ingelheim Investigational Site, Sainte-Foy

1237.4.0204 Boehringer Ingelheim Investigational Site, Sherbrooke

1237.4.0207 Boehringer Ingelheim Investigational Site, Saskatoon

1237.4.4903 Boehringer Ingelheim Investigational Site, Berlin

1237.4.4907 Boehringer Ingelheim Investigational Site, Erfurt

1237.4.4902 Boehringer Ingelheim Investigational Site, Gauting

1237.4.4908 Boehringer Ingelheim Investigational Site, Halle

1237.4.4906 Boehringer Ingelheim Investigational Site, Neuruppin

1237.4.4904 Boehringer Ingelheim Investigational Site, Rüdersdorf

1237.4.4901 Boehringer Ingelheim Investigational Site, Weinheim